Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
Like
Facebook
Tweet
AIBDR 4.20-4.21
Optimized Care for Patients With IBD: The Potential Benefits of Interleukin Inhibitors
Friday, April 21, 2023
9:15 AM – 9:45 AM
.
Speaker(s)
Gil Y. Melmed, MD, MS, FACG, AGAF
Cedars-Sinai Medical Center
Los Angeles, California
Disclosure(s):
Gil Y. Melmed, MD, MS, FACG, AGAF
: disclosed no relevant financial relationship with any ineligible company (commercial interest).
This session is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Learning Objectives:
Summarize the potential role of IL inhibitors in the treatment of IBD
Evaluate key efficacy and safety data for approved and emerging interleukin (IL)-12/23 and IL-23p19 inhibitors for the management of IBD
Incorporate shared decision-making, consistent communication, and consideration of the patient perspective into the care strategy of patients with IBD